MRTX1133
AXP000026.1 · Targeted small molecule
- Platform
- small molecule
- Targets
- KRAS
- Originator
- Mirati Therapeutics
- Sponsor
- Bristol Myers Squibb
Names
| Name | Type | Source |
|---|---|---|
| MRTX1133 | preferred name, code | curator, ncit |
Cross-references
- NCI Thesaurus
- C200319
- FDA UNII
- DU32DM9CHD
Approvals
No regulatory approval recorded.
Clinical trials (1)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT05737706 | Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation | Terminated | Phase 1 | 2023-03-06 | 2025-03-10 | 63 | Advanced Solid Tumor; Colo-rectal Cancer; Non-small Cell Lung Cancer; Pancreatic Adenocarcinoma; Solid Tumor |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 40740271 | Rare Case of Duodenal Metastasis From Colon Cancer: Review of Literature and Insights on Novel Therapies. | Case reports in gastrointestinal medicine | 2025 | name in abstract: MRTX1133 |
Other papers
Preclinical studies, reviews and other papers that name it, newest 100 shown.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41129140 | Dual Inhibitors of KRASG12D and HSP90 Are Effective against KRASG12D Inhibitor Resistance. | Molecular cancer therapeutics | 2026 | name in abstract: MRTX1133 |
| PMID 41379561 | HDAC5 deficiency induces intrinsic resistance to KRAS inhibition by disrupting c-Myc acetylation-ubiquitination homeostasis. | The Journal of clinical investigation | 2026 | name in abstract: MRTX1133 |
| PMID 41419408 | Targeted and immunotherapy strategies in pancreatic ductal adenocarcinoma: Recent developments and insights. | Hepatobiliary & pancreatic diseases international : HBPD INT | 2026 | name in abstract: MRTX1133 |
| PMID 41432073 | Discovery of Pyrazoloquinazoline Analogues as Orally Bioavailable KRAS-G12D Inhibitors. | Journal of medicinal chemistry | 2026 | name in abstract: MRTX1133 |
| PMID 41456631 | Dual Inhibition of KRAS G12D and PI3K/BRD4 signaling overcomes therapeutic resistance in pancreatic cancer. | Acta biomaterialia | 2026 | name in abstract: MRTX1133 |
| PMID 41501279 | Antimetastatic effects of MRTX1133 KRAS G12D specific inhibitor in a liver metastatic model of pancreatic ductal adenocarcinoma. | Scientific reports | 2026 | name in title: MRTX1133 |
| PMID 41506251 | In-Source Fragmentation of Pyrrolidine-Containing KRAS Scaffolds Leads to Enhanced Structure Elucidation and Tandem Mass Spectral Quality. | Journal of the American Society for Mass Spectrometry | 2026 | name in abstract: MRTX1133 |
| PMID 41513443 | KRAS mutation-driven O-GlcNAcylation of CLDN18.2 enhances the progression of pancreatic cancer and reduces the efficacy of CLDN18.2-targeted therapy. | Gut | 2026 | name in abstract: MRTX1133 |
| PMID 41519889 | Structure of SHOC2-KRAS-PP1C complex reveals RAS isoform-specific determinants and insights into targeting complex assembly by RAS inhibitors. | Nature communications | 2026 | name in abstract: MRTX1133 |
| PMID 41527355 | Resistance to the KRASG12D Inhibitor MRTX1133 Is Associated with Increased Sensitivity to BET Inhibition. | Molecular cancer therapeutics | 2026 | name in title: MRTX1133 |
| PMID 41542622 | The combination of BCL-xL PROTAC and mTOR inhibitor sensitizes pancreatic ductal adenocarcinoma to KRASG12D inhibitor treatment by enhancing apoptosis induction. | bioRxiv : the preprint server for biology | 2026 | name in abstract: MRTX1133 |
| PMID 41556452 | Ferritin-based nanocarrier delivery of KRAS G12D inhibitor in pancreatic adenocarcinoma cells and patient-derived organoids: A novel approach for treatment. | Protein science : a publication of the Protein Society | 2026 | name in abstract: MRTX1133 |
| PMID 41604371 | Computational repurposing of approved drugs targeting KRAS G12D and EGFR for colorectal cancer therapy. | PloS one | 2026 | name in abstract: MRTX1133 |
| PMID 41636798 | Exploring the GDP binding to KRas WT, G12C, G12D, G12R, and G12V and bound with MRTX1133 using steered molecular dynamics. | European biophysics journal : EBJ | 2026 | name in title: MRTX1133 |
| PMID 41679196 | Discovery of KRAS-G12D degraders via exploration of various E3 ligases. | European journal of medicinal chemistry | 2026 | name in abstract: MRTX1133 |
| PMID 41722442 | FGTI-2734 prevents ERK-mediated resistance and enhances MRTX1133 efficacy in KRAS G12D pancreatic cancer. | European journal of cancer (Oxford, England : 1990) | 2026 | name in title: MRTX1133 |
| PMID 41735281 | Combination of PARP and KRASG12D inhibitors enhances therapeutic efficacy by exploiting vulnerabilities in PDAC. | Nature communications | 2026 | name in abstract: MRTX1133 |
| PMID 41813757 | Screening of kinase inhibitors in the triple negative KRAS G13D-mutated MDA-MB-231 breast cancer cell line. | Scientific reports | 2026 | name in abstract: MRTX1133 |
| PMID 41816298 | Pharmaco-genomic characterization of pancreatic and biliary tract cancer tumoroids for drug response. | iScience | 2026 | name in abstract: MRTX1133 |
| PMID 41822354 | Tumor microenvironment-activated ferritin nanovector enables enhanced tumor delivery of KRASG12C inhibitors and degraders. | Frontiers in cell and developmental biology | 2026 | name in abstract: MRTX1133 |
| PMID 41830517 | MRTX1133 suppresses ERK signaling but elicits context-dependent antiproliferative responses in KRAS (G12C) cancer cells. | Molecular cancer therapeutics | 2026 | name in title: MRTX1133 |
| PMID 41899524 | The Combination of a BCL-xL PROTAC and an mTOR Inhibitor Sensitizes Pancreatic Ductal Adenocarcinoma to KRASG12D Inhibitor Treatment. | Cancers | 2026 | name in abstract: MRTX1133 |
| PMID 41951768 | High-throughput screening identifies NT-1 that synergizes with MRTX1133 against acquired resistant KRASG12D colorectal cancer. | NPJ precision oncology | 2026 | name in title: MRTX1133 |
| PMID 41969551 | Emerging KRAS G12D inhibitor in the treatment of digestive system tumors: opportunities and challenges. | Translational gastroenterology and hepatology | 2026 | name in abstract: MRTX1133 |
| PMID 41993359 | KRAS inhibition is an effective therapy for appendiceal adenocarcinoma. | bioRxiv : the preprint server for biology | 2026 | name in abstract: MRTX1133 |
| PMID 42030031 | GAP mimetic activity of pan-Ras TCI daraxonrasib synergizes with K-Ras Switch-II pocket inhibition. | Biological chemistry | 2026 | name in abstract: MRTX1133 |
| PMID 42038352 | KRAS (G12D)-selective inhibitor MRTX1133 suppresses proliferation and differentially modulates chemosensitivity in ovarian mucinous carcinoma. | Oncology letters | 2026 | name in title: MRTX1133 |
| PMID 42041157 | MRTX1133 Suppresses ERK Signaling but Elicits Context-Dependent Antiproliferative Responses in KRAS (G12C) Cancer Cells. | Molecular cancer therapeutics | 2026 | name in title: MRTX1133 |
| PMID 42054368 | Fra-2 controls the response to the KRAS inhibitor MRTX-1133 in pancreatic ductal adenocarcinoma. | Proceedings of the National Academy of Sciences of the United States of America | 2026 | name in title: MRTX1133 |
| PMID 42079131 | Characterization and therapeutic suppression of KEAP1-NRF2-driven resistance to KRAS inhibitors in pancreatic and lung cancer. | bioRxiv : the preprint server for biology | 2026 | name in abstract: MRTX1133 |
| PMID 42126708 | Identification of natural compounds targeting the KRAS G12D mutation in pancreatic cancer through integrated in silico and in vitro approaches. | Journal of computer-aided molecular design | 2026 | name in abstract: MRTX1133 |
| PMID 42191046 | Targeting Oncomucin-Driven Immunosuppression Improves the Efficacy of K-rasG12D Inhibition in Pancreatic Cancer. | Gastroenterology | 2026 | name in abstract: MRTX1133 |
| PMID 42198429 | A Molecular-Protein Fusion Framework for Rapid Virtual Screening: Accelerating Lead Discovery for "Undruggable'' Oncogenic Targets. | Pharmaceuticals (Basel, Switzerland) | 2026 | name in abstract: MRTX1133 |
| PMID 42209458 | Efficacy of dual KRASG12D-EGFR blockade versus triple combinations in patient-derived models of KRASG12D-mutant colorectal cancer. | Cell death & disease | 2026 | name in abstract: MRTX1133 |
| PMID 42221851 | Stability-Driven Pose Prediction and Ligand Design via Contact Persistence Analysis from Molecular Dynamics Simulations. | Computational and structural biotechnology journal | 2026 | name in abstract: MRTX1133 |
| PMID 42259905 | Variable efficacy of the non-covalent KRASG12D inhibitor (MRTX-1133) with obesity in murine pancreatic cancer. | NPJ precision oncology | 2026 | name in title: MRTX1133 |
| PMID 42298062 | Targeting WFS1 overcomes KRASG12D dependency and adaptive resistance to KRAS inhibition in pancreatic cancer. | NPJ precision oncology | 2026 | name in abstract: MRTX1133 |
| PMID 42321850 | Palbociclib targets β-catenin for degradation and synergizes with KRAS or ERK5 inhibition in colorectal cancer preclinical models. | Journal of translational medicine | 2026 | name in abstract: MRTX1133 |
| PMID 42392864 | USP20 promotes CD8+ T cell exhaustion and impairs KRASG12D inhibitor efficacy by orchestrating cholesterol metabolism and autophagy in pancreatic cancer. | Gut | 2026 | name in abstract: MRTX1133 |
| PMID 42393724 | KRAS inhibition is an effective therapy for appendiceal adenocarcinoma. | Journal of hematology & oncology | 2026 | name in abstract: MRTX1133 |
| PMID 42398486 | In Silico identification of natural and synthetic inhibitors targeting KRAS mutants (G12D, G12V, and G12C) and wild-type in pancreatic cancer. | Journal of molecular graphics & modelling | 2026 | name in abstract: MRTX1133 |
| PMID 42399085 | Dysregulated sphingolipid metabolismdrives pancreatic carcinogenesis through plasma membrane Kras enrichment. | Gut | 2026 | name in abstract: MRTX1133 |
| PMID 42436354 | CDK8 remodels the tumor microenvironment and promotes resistance to KRASG12D inhibitors and daraxonrasib in PDAC. | The EMBO journal | 2026 | name in abstract: MRTX1133 |
| PMID 42490421 | KRASG12D inhibition reprograms the tumor-induced immunosuppressive environment and enhances NK cell-mediated antitumor immunity. | Science advances | 2026 | name in abstract: MRTX1133 |
| PMID 42523398 | Concurrent Stereotactic Body Radiation Therapy and KRAS Inhibition Synergistically Improve Pre-clinical Pancreatic Cancer Treatment. | bioRxiv : the preprint server for biology | 2026 | name in abstract: MRTX1133 |
| PMID 42580447 | Targeted KRAS suppression in colorectal cancer via in vivo self-assembled siRNAs encapsulated in endogenous small extracellular vesicles. | Journal of controlled release : official journal of the Controlled Release Society | 2026 | name in abstract: MRTX1133 |
| PMID 42603637 | Discovery of a Potent and Selective KRAS G12D Degrader based on PROTAC Degradation. | European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences | 2026 | name in abstract: MRTX1133 |
| PMID 42615854 | Progress and challenges in the design and development of selective KRAS G12D-targeted drug discovery: inhibitors, degraders and emerging therapeutic strategies. | Future medicinal chemistry | 2026 | name in abstract: MRTX1133 |
| PMID 42649211 | Oncogenic Kras targeting with MRTX1133 or Daraxonrasib specifically synergize with anti-CTLA4 to promote anti-tumor immunity in pancreatic cancer. | Nature communications | 2026 | name in title: MRTX1133 |
| PMID 42667948 | XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant pancreatic ductal adenocarcinoma. | Cancer letters | 2026 | name in abstract: MRTX1133 |
| PMID 42678463 | Emerging Therapeutic Strategies for Non-G12C KRAS Mutations in Colorectal Cancer: Focusing on G12D and G12V. | Journal of gastrointestinal cancer | 2026 | name in abstract: MRTX1133 |
| PMID 42693727 | Identification of the Potential of Plant-Derived Agents to Act as KRAS G12D Inhibitors Through Molecular Docking, Molecular Dynamics Simulations, and MMGBSA. | Current pharmaceutical design | 2026 | name in abstract: MRTX1133 |
| PMID 42720810 | Beyond KRASG12C: emerging therapeutic strategies, patent landscape, and clinical progress in targeting KRAS-mutant cancers. | Medical oncology (Northwood, London, England) | 2026 | name in abstract: MRTX1133 |
| PMID 42771504 | IRE1α-XBP1s signaling links lipid homeostasis to hypoxic maladaptation and KRAS inhibitor responses in pancreatic ductal adenocarcinoma. | Proceedings of the National Academy of Sciences of the United States of America | 2026 | name in abstract: MRTX1133 |
| PMID 42841489 | Variant-selective and pan-RAS inhibitors enhance targeted agent activity in patient-derived multi-cell type tumor spheroids. | Molecular cancer therapeutics | 2026 | name in abstract: MRTX1133 |
| PMID 42956743 | KRASG12D-targeted therapy sensitivity depends on interferon signaling activation in pancreatic cancer. | Cancer cell | 2026 | name in abstract: MRTX1133 |
| PMID 42971499 | Saturation mutagenesis library screening identifies on-target secondary resistance mutations in KRASG12D-selective inhibitors. | Cancer letters | 2026 | name in abstract: MRTX1133 |
| PMID 42984346 | Variant-Selective and Pan-RAS Inhibitors Enhance Targeted Agent Activity in Patient-Derived Multi-cell-type Tumor Spheroids. | Molecular cancer therapeutics | 2026 | name in abstract: MRTX1133 |
| PMID 42988458 | Simultaneous LC-MS/MS quantification of four KRAS inhibitors (RMC-6236, RMC-9805, RMC-7977, and MRTX1133) in human plasma: toward therapeutic drug monitoring in pancreatic ductal adenocarcinoma. | Bioanalysis | 2026 | name in title: MRTX1133 |
| PMID 39400496 | Targeting KRAS-mutant pancreatic cancer through simultaneous inhibition of KRAS, MEK, and JAK2. | Molecular oncology | 2025 | name in abstract: MRTX1133 |
| PMID 39651222 | Multimetric MRI Captures Early Response and Acquired Resistance of Pancreatic Cancer to KRAS Inhibitor Therapy. | bioRxiv : the preprint server for biology | 2025 | name in abstract: MRTX1133 |
| PMID 39657309 | MRTX1133 attenuates KRASG12D mutated-colorectal cancer progression through activating ferroptosis activity via METTL14/LINC02159/FOXC2 axis. | Translational oncology | 2025 | name in title: MRTX1133 |
| PMID 39664928 | Dynamic conformational equilibria in the active states of KRAS and NRAS. | RSC chemical biology | 2025 | name in abstract: MRTX1133 |
| PMID 39710177 | Decoding KRAS dynamics: Exploring the impact of mutations and inhibitor binding. | Archives of biochemistry and biophysics | 2025 | name in abstract: MRTX1133 |
| PMID 39786607 | Development of a new flippase-dependent mouse model for red fluorescence-based isolation of KRASG12D oncogene-expressing tumor cells. | Transgenic research | 2025 | name in abstract: MRTX1133 |
| PMID 39810420 | Pancreatic cancer-derived extracellular vesicles enhance chemoresistance by delivering KRASG12D protein to cancer-associated fibroblasts. | Molecular therapy : the journal of the American Society of Gene Therapy | 2025 | name in abstract: MRTX1133 |
| PMID 39879317 | AGER-dependent macropinocytosis drives resistance to KRAS-G12D-targeted therapy in advanced pancreatic cancer. | Science translational medicine | 2025 | name in abstract: MRTX1133 |
| PMID 39970873 | KRASG12D-driven pentose phosphate pathway remodeling imparts a targetable vulnerability synergizing with MRTX1133 for durable remissions in PDAC. | Cell reports. Medicine | 2025 | name in title: MRTX1133 |
| PMID 40073053 | SOS1 inhibitor BI-3406 shows in vivo antitumor activity akin to genetic ablation and synergizes with a KRASG12D inhibitor in KRAS LUAD. | Proceedings of the National Academy of Sciences of the United States of America | 2025 | name in abstract: MRTX1133 |
| PMID 40082968 | ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma. | Molecular cancer | 2025 | name in abstract: MRTX1133 |
| PMID 40093186 | Distinct small molecule inhibitors of Kras specifically prime CTLA4 blockade therapy to transcriptionally reprogram Tregs and overcome resistance to suppress pancreas cancer. | bioRxiv : the preprint server for biology | 2025 | name in abstract: MRTX1133 |
| PMID 40146324 | Enhancing KRAS G12D inhibitor sensitivity in pancreatic cancer through SHP2/PI3K pathway. | Medical oncology (Northwood, London, England) | 2025 | name in abstract: MRTX1133 |
| PMID 40210129 | Combinatorial screen with apoptosis pathway targeted agents alrizomadlin, pelcitoclax, and dasminapant in multi-cell type tumor spheroids. | SLAS discovery : advancing life sciences R & D | 2025 | name in abstract: MRTX1133 |
| PMID 40260640 | Multimetric MRI Captures Early Response and Acquired Resistance of Pancreatic Cancer to KRAS Inhibitor Therapy. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2025 | name in abstract: MRTX1133 |
| PMID 40268231 | Switch II Pocket Inhibitor Allosterically Freezes KRASG12D Nucleotide-binding Site and Arrests the GTPase Cycle. | Journal of molecular biology | 2025 | name in abstract: MRTX1133 |
| PMID 40382842 | KRAS inhibition reverses chemotherapy resistance promoted by therapy-induced senescence-like in pancreatic ductal adenocarcinoma. | Translational oncology | 2025 | name in abstract: MRTX1133 |
| PMID 40420168 | Targeting DNA helicase CMG complex and NFκB2-driven drug-resistant transcriptional axis to effectively treat KRASG12D-mutated pancreatic cancer. | Experimental hematology & oncology | 2025 | name in abstract: MRTX1133 |
| PMID 40430514 | Design, Synthesis, Anticancer Evaluation and Molecular Docking of Pyrimidine, Pyrido[4,3-d]pyrimidine and 5,6,7,8-Tetrahydropyrido[3,4-d]pyrimidine Derivatives as Novel KRAS-G12D Inhibitors and PROTACs. | Pharmaceuticals (Basel, Switzerland) | 2025 | name in abstract: MRTX1133 |
| PMID 40437561 | Acetylation-induced degradation of ECHS1 enhances BCAA accumulation and proliferation in KRAS-mutant colorectal cancer. | Journal of experimental & clinical cancer research : CR | 2025 | name in abstract: MRTX1133 |
| PMID 40439998 | Combination Therapy of Avutometinib and MRTX1133 Synergistically Suppresses Cell Growth by Inducing Apoptosis in KRASG12D-Mutated Pancreatic Cancer. | Molecular cancer therapeutics | 2025 | name in title: MRTX1133 |
| PMID 40463163 | Resistance to the KRASG12D Inhibitor MRTX1133 is Associated with Increased Sensitivity to BET Inhibition. | bioRxiv : the preprint server for biology | 2025 | name in title: MRTX1133 |
| PMID 40470182 | RNA processing kinase inhibitors and epigenetic inhibitors in combination with oncology drugs or investigational agents in multi-cell type patient-derived tumor cell line spheroids. | Research square | 2025 | name in abstract: MRTX1133 |
| PMID 40624835 | Drugging the 'undruggable' KRAS: breakthroughs, challenges, and opportunities in pancreatic cancer. | Cancer biology & medicine | 2025 | name in abstract: MRTX1133 |
| PMID 40631072 | High Throughput Screening Identifies Small Molecules that Synergize with MRTX1133 Against Acquired Resistant KRAS G12D Mutated CRC. | bioRxiv : the preprint server for biology | 2025 | name in title: MRTX1133 |
| PMID 40652232 | Investigation of potential KRASG12D inhibitors: a comparative study between MRTX1133 and natural compounds via computational structural biology approaches. | BMC research notes | 2025 | name in title: MRTX1133 |
| PMID 40666480 | Identification of Novel pan-KRAS Inhibitors via Structure-Based Drug Design, Scaffold Hopping, and Biological Evaluation. | ACS medicinal chemistry letters | 2025 | name in abstract: MRTX1133 |
| PMID 40743812 | The design and synthesis of selective and potent selenium-containing KRASG12D inhibitors. | European journal of medicinal chemistry | 2025 | name in abstract: MRTX1133 |
| PMID 40755231 | Co-targeting KRASG12D and the HER family is efficacious in colorectal cancer. | Carcinogenesis | 2025 | name in abstract: MRTX1133 |
| PMID 40780213 | A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers. | Cancer cell | 2025 | name in abstract: MRTX1133 |
| PMID 40791564 | CDK8 remodels the tumor microenvironment to resist the therapeutic efficacy of targeted KRAS G12D inhibition in pancreatic ductal adenocarcinoma. | bioRxiv : the preprint server for biology | 2025 | name in abstract: MRTX1133 |
| PMID 40800005 | CDCP1-targeting ADC outperforms standard therapies in Ras-mutant pancreatic cancer. | Molecular therapy. Oncology | 2025 | name in abstract: MRTX1133 |
| PMID 40805153 | Treatment of KRAS-Mutated Pancreatic Cancer: New Hope for the Patients? | Cancers | 2025 | name in abstract: MRTX1133 |
| PMID 40848084 | Simulating tumor complexity: 3D pancreatic tumor spheroid model for improved drug screening. | Human cell | 2025 | name in abstract: MRTX1133 |
| PMID 40886852 | Harmine suppresses pancreatic cancer through DYRK1A-mediated hyper-activated RAS/MAPK inhibition. | Biochemical pharmacology | 2025 | name in abstract: MRTX1133 |
| PMID 40938473 | RNA processing kinase inhibitors and epigenetic inhibitors in combination with oncology drugs or investigational agents in multi-cell type patient-derived tumor cell line spheroids. | Cancer chemotherapy and pharmacology | 2025 | name in abstract: MRTX1133 |
| PMID 40997784 | ZJK-807: A Selective PROTAC Degrader of KRASG12D Overcoming Resistance in Pancreatic Cancer. | Journal of medicinal chemistry | 2025 | name in abstract: MRTX1133 |
| PMID 41000780 | VEGFR2 blockade overcomes acquired KRAS G12D inhibitor resistance driven by PI3Kγ activation. | bioRxiv : the preprint server for biology | 2025 | name in abstract: MRTX1133 |
| PMID 41017113 | Expanding the Chemistry of Acyl Diazo Electrophile as a Tunable Warhead for Covalent Targeting of KRAS (G12D) Mutant. | Journal of medicinal chemistry | 2025 | name in abstract: MRTX1133 |
| PMID 41086055 | Targeting KRAS Inhibitor-Resistant Pancreatic Cancer with an MUC1-C Antibody-Drug Conjugate. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2025 | name in abstract: MRTX1133 |
| PMID 41130420 | Hybrid nanovesicles enhance antitumor efficacy in KRAS-mutant non-small cell lung cancer. | Journal of controlled release : official journal of the Controlled Release Society | 2025 | name in abstract: MRTX1133 |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| F31CA309960 | Leveraging pIgR-mediated endocytosis of dimeric IgA in PDAC Treatment | UNIV OF NORTH CAROLINA CHAPEL HILL | SILVA, HARRISON | 2026–2026 | name in abstract: MRTX1133 |
| R01CA296410 | Optimization of an active mutant KRAS peptide vaccine in colorectal cancer | JOHNS HOPKINS UNIVERSITY | AZAD, NILOFER S. | 2025–2026 | name in abstract: MRTX1133 |
| R01CA303154 | Interactive Functional Dynamics of Human K-Ras, Its Oncogenic Mutants and their Binding Partners | OHIO STATE UNIVERSITY | BRUSCHWEILER, RAFAEL | 2026–2026 | name in abstract: MRTX1133 |
| R21CA309360 | Identifying immune-mediated mechanisms of RAS inhibitor efficacy and resistance in pancreatic cancer | UNIV OF NORTH CAROLINA CHAPEL HILL | MILNER, JOHN JUSTIN | 2026–2026 | name in abstract: MRTX1133 |
| R03CA304041 | Targeting the HER Family in KRAS Mutant Colorectal Cancer | UNIVERSITY OF CINCINNATI | GARRETT, JOAN T. | 2025–2025 | name in abstract: MRTX1133 |
| R21CA286372 | The Role of the Tumor Microenvironment in Resistance to Oncogenic KRAS Inhibition in Lung Cancer | UNIVERSITY OF MICHIGAN AT ANN ARBOR | GALBAN, STEFANIE | 2024–2025 | name in abstract: MRTX1133 |
| R21CA297690 | Noncovalent interaction of mutant KRAS inhibitors | DUKE UNIVERSITY | CHI, JEN-TSAN ASHLEY | 2025–2025 | name in abstract: MRTX1133 |
Notes
KRAS G12D non-covalent. No INN found. BMS reported discontinued (ApexOnco 2025-03-05). Reported discontinued by Bristol Myers Squibb (ApexOnco, 2025-03-05); kept because trials and papers use the name.
How to cite
MRTX1133 (AXP000026.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000026.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.